Skip to main content
Premium Trial:

Request an Annual Quote

Myriad to Conduct BRCA Testing for Abbott Drug Study

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it will conduct BRCA testing on patients enrolled in an Abbott Laboratories drug study.

Myriad will perform BRCA1 and BRCA2 mutation testing on patients in the Phase III, multi-center study of an Abbott drug for metastatic breast cancer. The Salt Lake City-based firm said that the agreement is similar to a previous agreement for a Phase II study of the same drug.

Myriad will use its BRACAnalysis test to determine the mutation status of the patients and provide standard test reports to clinicians at each study site.

The firms did not disclose financial or other details of the agreement.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.